Katie Peng Sells 1,006 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the transaction, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. This trade represents a 3.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scholar Rock Stock Performance

Scholar Rock stock traded up $0.09 during trading hours on Wednesday, hitting $33.97. The stock had a trading volume of 913,387 shares, compared to its average volume of 1,153,644. The company has a market cap of $3.22 billion, a PE ratio of -14.46 and a beta of 0.59. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a 50-day moving average of $39.03 and a two-hundred day moving average of $31.86. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Truist Financial raised their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. HC Wainwright lifted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Wedbush reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Scholar Rock currently has an average rating of “Buy” and an average price target of $40.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its position in shares of Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock valued at $589,316,000 after acquiring an additional 3,439,215 shares during the last quarter. Marshall Wace LLP boosted its stake in Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock worth $127,301,000 after purchasing an additional 2,732,546 shares during the period. Norges Bank bought a new position in shares of Scholar Rock during the fourth quarter worth about $86,043,000. Fairmount Funds Management LLC acquired a new stake in Scholar Rock in the 4th quarter valued at $84,839,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Scholar Rock in the 4th quarter valued at approximately $68,930,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.